If there has been anything stable in the pharmaceutical industry, it is the notion that–with pipelines relatively dry--late-stage deal prices will continue to rise. And statistically, they do. For Phase II and III deals valued at more than $10 million and signed since January 2003, the average up-front fee (including any equity payments) has risen to $43.8 million, compared to about $31.1 million for deals signed in 2002.
And yet, despite the increasing average deal price, the number of big deals is down. "I haven't seen any decrease...


